Arcadia Investment Management Corp MI Makes New Investment in Artivion, Inc. (NYSE:AORT)

Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion, Inc. (NYSE:AORT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,493 shares of the company’s stock, valued at approximately $43,000.

Other hedge funds have also recently made changes to their positions in the company. Quarry LP increased its holdings in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after buying an additional 820 shares during the period. R Squared Ltd acquired a new stake in shares of Artivion in the fourth quarter worth $39,000. Venturi Wealth Management LLC purchased a new position in shares of Artivion during the fourth quarter worth $78,000. GAMMA Investing LLC lifted its position in Artivion by 21.8% during the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock valued at $79,000 after purchasing an additional 497 shares during the period. Finally, KBC Group NV boosted its holdings in Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AORT has been the subject of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price target on shares of Artivion in a report on Tuesday, January 28th. Finally, Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $31.80.

Insider Buying and Selling at Artivion

In other news, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $29.66, for a total value of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,017 shares of company stock valued at $600,007. Company insiders own 8.10% of the company’s stock.

Artivion Price Performance

Shares of Artivion stock opened at $28.29 on Friday. The firm has a market cap of $1.19 billion, a PE ratio of -1,414.70 and a beta of 1.75. Artivion, Inc. has a twelve month low of $18.38 and a twelve month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $29.77 and a 200 day moving average price of $27.77.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.